Johnson & Johnson (NYSE:JNJ) Holdings Raised by Guinness Atkinson Asset Management Inc

Guinness Atkinson Asset Management Inc lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 24.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,542 shares of the company’s stock after purchasing an additional 700 shares during the quarter. Guinness Atkinson Asset Management Inc’s holdings in Johnson & Johnson were worth $498,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Sofos Investments Inc. raised its stake in shares of Johnson & Johnson by 172.0% during the first quarter. Sofos Investments Inc. now owns 1,148 shares of the company’s stock valued at $33,000 after purchasing an additional 726 shares in the last quarter. Altshuler Shaham Ltd bought a new stake in shares of Johnson & Johnson during the first quarter valued at about $35,000. Lake Point Wealth Management raised its position in Johnson & Johnson by 144.4% in the first quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock worth $38,000 after acquiring an additional 169 shares in the last quarter. Lion Street Advisors LLC bought a new stake in Johnson & Johnson in the first quarter worth about $45,000. Finally, SeaBridge Investment Advisors LLC raised its position in Johnson & Johnson by 160.0% in the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock worth $46,000 after acquiring an additional 200 shares in the last quarter. Institutional investors and hedge funds own 68.44% of the company’s stock.

JNJ has been the topic of several research reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $168.00 price target on shares of Johnson & Johnson in a research report on Tuesday, April 28th. Bank of America reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, July 20th. SVB Leerink reiterated an “outperform” rating on shares of Johnson & Johnson in a research report on Wednesday, July 15th. Wells Fargo & Co upgraded shares of Johnson & Johnson to a “hold” rating in a research report on Wednesday, April 22nd. Finally, UBS Group cut shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $163.00 to $160.00 in a research report on Tuesday, April 28th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Buy” and a consensus target price of $163.38.

In other Johnson & Johnson news, EVP Ashley Mcevoy sold 29,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the transaction, the executive vice president now owns 21,682 shares of the company’s stock, valued at approximately $3,197,444.54. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.27% of the company’s stock.

NYSE:JNJ opened at $145.76 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 1.05. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The stock’s 50-day moving average is $144.04 and its two-hundred day moving average is $144.14. The stock has a market cap of $383.76 billion, a PE ratio of 21.31, a price-to-earnings-growth ratio of 3.23 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The company had revenue of $18.34 billion for the quarter, compared to analysts’ expectations of $17.73 billion. During the same quarter in the previous year, the business posted $2.58 EPS. The business’s revenue for the quarter was down 10.8% on a year-over-year basis. On average, equities research analysts anticipate that Johnson & Johnson will post 7.85 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a dividend of $1.01 per share. The ex-dividend date of this dividend is Monday, August 24th. This represents a $4.04 annualized dividend and a yield of 2.77%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: What is a stock buyback?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.